Ormutivimab is a biosimilar monoclonal antibody that specifically targets the G glycoprotein of the rabies virus. Developed as a research-grade molecule, this anti-G glycoprotein antibody offers a high-affinity, reproducible alternative for studying viral entry mechanisms, neutralization pathways, and host-pathogen interactions.
Molecular Structure
The biosimilar Ormutivimab is a recombinant IgG1 monoclonal antibody constructed using hybridoma or recombinant expression systems. It mirrors the original therapeutic structure in amino acid sequence, glycosylation pattern (to the extent possible in non-clinical systems), and binding epitopes. The antibody is composed of two identical heavy chains and two identical light chains, forming a Y-shaped immunoglobulin structure with antigen-binding (Fab) regions and an Fc domain.
The variable regions in the Fab arms are engineered to ensure high specificity toward a conformational epitope on the G glycoprotein of the rabies virus, a critical component of viral attachment and membrane fusion.
Biological Activity and
Mechanism of Action
Ormutivimab binds with high affinity to the G (glycoprotein) envelope protein, which is essential for rabies virus infectivity. The G protein is a key therapeutic target in both prophylactic and therapeutic contexts due to its role in virus-host cell interaction.
Upon binding, Ormutivimab neutralizes the virus by:
Blocking attachment to host neuronal receptors such as the nicotinic acetylcholine receptor (nAChR) and neural cell adhesion molecule (NCAM)
Preventing membrane fusion and viral entry
Triggering immune-mediated clearance through Fc-effector functions such as ADCC (antibody-dependent cellular cytotoxicity) and phagocytosis
Research and Preclinical Applications
This research-grade antibody is widely used in:
Neutralization assays for studying rabies viral inhibition mechanisms
Epitope mapping and structural biology studies of glycoprotein–antibody interactions
Comparative studies between biosimilars and original anti-rabies biologics
Assay development for diagnostics targeting rabies G protein
Its consistent performance and known binding profile make Ormutivimab an excellent tool for academic, diagnostic, and early-stage preclinical research involving rabies virus and antibody engineering.
Advantages of Using Ormutivimab Biosimilar
High batch-to-batch consistency
Cost-effective alternative to clinical-grade antibodies
Validated specificity for rabies G glycoprotein
Suitable for in vitro and in vivo use (non-human)
Conclusion
Ormutivimab Biosimilar offers researchers a powerful tool to explore viral immunology, advance rabies virus studies, and evaluate antibody-based therapeutics targeting the G glycoprotein. While not intended for therapeutic use in humans, its value in the laboratory as a model antibody and reference for therapeutic target validation is substantial.
Reviews
There are no reviews yet.